Ocean Biomedical, Inc. (OCEA)

USD 0.58

(-6.9%)

Market Cap (In USD)

20.29 Million

Revenue (In USD)

-

Net Income (In USD)

565.47 Thousand

Avg. Volume

87.37 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.52-7.79
PE
-
EPS
-
Beta Value
1.529
ISIN
US67644C1045
CUSIP
67644P105
CIK
1836612
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Elizabeth Ng M.B.A.
Employee Count
-
Website
http://www.oceanbiomedical.com
Ipo Date
2021-11-08
Details
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.